# Dr. Yvonne Linney: executive, Artificial

Canonical ID: `82c6e8f1-4b0e-4778-9ece-44113b681317`

Chief Operating Officer of Artificial Inc., a lab automation company providing a first-of-its-kind orchestration platform for life science labs. Joined Artificial in January 2021, bringing 30+ years of executive experience at industry-leading life sciences and diagnostic companies. Previously COO and then CEO of Transcriptic (now Strateos), where she brokered a multi-year, multi-million dollar agreement with Eli Lilly. Before that, VP and GM of the Life Science Solutions Division at Agilent Technologies, where she established a $1.5B Life Science Group. Also held senior roles at Bayer Diagnostics (now Siemens Healthcare), Caliper Life Sciences, and Amersham International (now GE Healthcare). Serves on the board of Bionano Genomics. Holds a BS in Microbiology and Virology from Warwick University and a PhD in Genetics from Leicester University, UK.

- **Nationality:** British

## Current roles (1)

- [Artificial](https://registry.deploy.report/companies/artificial-inc.md) COO

## Sources (3)

1. https://www.businesswire.com/news/home/20210119005125/en/Artificial-Inc.-Expands-Leadership-Team-and-Board-of-Directors-to-Catalyze-the-Labs-Digital-Revolution
2. https://ir.bionanogenomics.com/static-files/e7088a54-dafe-4471-8cb0-e6d557089e99
3. https://www.citybiz.co/article/365730/sengenics-appoints-yvonne-linney-phd-as-board-director/


_API: GET /v1/people/yvonne-linney · canonical URL: /people/yvonne-linney_